Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CD55 antibody (FITC)

CD55 Reactivity: Mouse WB, FACS Host: Rat Monoclonal 3D5 FITC
Catalog No. ABIN2191854
  • Target See all CD55 Antibodies
    CD55 (Complement Decay-Accelerating Factor (CD55))
    Reactivity
    • 110
    • 34
    • 7
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    Mouse
    Host
    • 69
    • 67
    • 6
    • 5
    • 3
    • 1
    • 1
    Rat
    Clonality
    • 81
    • 69
    • 2
    Monoclonal
    Conjugate
    • 73
    • 17
    • 15
    • 11
    • 5
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This CD55 antibody is conjugated to FITC
    Application
    • 97
    • 76
    • 47
    • 39
    • 33
    • 25
    • 16
    • 15
    • 14
    • 13
    • 9
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Flow Cytometry (FACS)
    Sterility
    0.2 μm filtered
    Clone
    3D5
    Top Product
    Discover our top product CD55 Primary Antibody
  • Application Notes
    For flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
    Restrictions
    For Research Use only
  • Buffer
    PBS, containing 1.0 % bovine serum albumin and 0.02 % sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C
    Storage Comment
    Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
    Expiry Date
    12 months
  • Lin, Fukuoka, Spicer, Ohta, Okada, Harris, Emancipator, Medof: "Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies." in: Immunology, Vol. 104, Issue 2, pp. 215-25, (2001) (PubMed).

    Harris, Spiller, Morgan: "Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities." in: Immunology, Vol. 100, Issue 4, pp. 462-70, (2000) (PubMed).

    Spiller, Goodfellow, Evans, Almond, Morgan: "Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF." in: The Journal of infectious diseases, Vol. 181, Issue 1, pp. 340-3, (2000) (PubMed).

    Spiller, Harris, Morgan: "Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells." in: Journal of immunological methods, Vol. 224, Issue 1-2, pp. 51-60, (1999) (PubMed).

  • Target
    CD55 (Complement Decay-Accelerating Factor (CD55))
    Alternative Name
    Complement Decay Accelerating Factor (CD55 Products)
    Synonyms
    CR antibody, CROM antibody, DAF antibody, TC antibody, Daf antibody, Daf-GPI antibody, Daf1 antibody, GPI-DAF antibody, CD55 molecule (Cromer blood group) antibody, CD55 molecule, decay accelerating factor for complement antibody, CD55 antibody, Cd55 antibody
    Background
    The monoclonal antibody 3D5 recognizes complement decay accelerating factor (DAF), also designated as CD55. Cells express on their surface several proteins which protect against complement attack, namely C receptor I (CR1), decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP). Mouse DAF (CD55) is a 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. DAF is broadly distributed among cells in contact with serum, including both haematopoietic and nonhaematopoietic cells. Although DAF does not have an essential role in controlling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells. Together with other complement regulators DAF protects self cells from autologous complement- mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. Aliases DAF (decay accelerating factor), CD55 Immunogen NRK cells expressing transmembrane-anchored mouse DAF
    Pathways
    Complement System, Regulation of Leukocyte Mediated Immunity
You are here:
Support